Related references
Note: Only part of the references are listed.Mathematics Students' Coping Behaviour, Happiness, and Self-efficacy in the New Normal: Correlation and K-means Cluster Analysis
Leomarich F. Casinillo
CANADIAN JOURNAL OF FAMILY AND YOUTH (2023)
Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression
Danya Muilwijk et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids
E. de Poel et al.
JOURNAL OF CYSTIC FIBROSIS (2022)
A role for AKT1 in nonsense-mediated mRNA decay
Martine Palma et al.
NUCLEIC ACIDS RESEARCH (2021)
Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids
Daniel K. Crawford et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients
Jia Xin Jiang et al.
STEM CELL REPORTS (2021)
Discovery of CFTR modulators for the treatment of cystic fibrosis
Miqueias Lopes-Pacheco et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase
Gommaar D'Hulst et al.
NATURE COMMUNICATIONS (2020)
Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids
Annelotte M. Vonk et al.
STAR PROTOCOLS (2020)
Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening
Yuhong Du et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2020)
Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression
Danya Muilwijk et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis
Gitte Berkers et al.
CELL REPORTS (2019)
High-Throughput Surface Liquid Absorption and Secretion Assays to Identify F508del CFTR Correctors Using Patient Primary Airway Epithelial Cultures
Allison Berg et al.
SLAS DISCOVERY (2019)
Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
Stephanie Chin et al.
CELLS (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
Norman Sachs et al.
CELL (2018)
Intestinal Failure and Aberrant Lipid Metabolism in Patients With DGAT1 Deficiency
Jorik M. van Rijn et al.
GASTROENTEROLOGY (2018)
Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function
Karin M. de Winter-de Groot et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Atul Bhardwaj et al.
NATURE COMMUNICATIONS (2017)
Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis
Johanna F. Dekkers et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity
Annalisa Bonifacio et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2015)
Different effects of statins on induction of diabetes mellitus: an experimental study
Wang Zhao et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Cystic fibrosis: An inherited disease affecting mucin-producing organs
Camille Ehre et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2014)
Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy
T. Grabinger et al.
CELL DEATH & DISEASE (2014)
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
Elton Kerem et al.
LANCET RESPIRATORY MEDICINE (2014)
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene
Patrick R. Sosnay et al.
NATURE GENETICS (2013)
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Johanna F. Dekkers et al.
NATURE MEDICINE (2013)
Identification of Synergistic Combinations of F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
Stephen Lin et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2010)
Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations
Igor Nudelman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells
NE Kreiselmeier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2003)
Use of coefficient of variation in assessing variability of quantitative assays
GF Reed et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2002)
Share Paper
